Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2017

01-04-2017 | Colorectal Cancer

Survival Outcome and Risk of Metachronous Colorectal Cancer After Surgery in Lynch Syndrome

Authors: Tae Jun Kim, MD, Eun Ran Kim, MD, Sung Noh Hong, MD, PhD, Young-Ho Kim, MD, PhD, Jung Wook Huh, MD, PhD, Yoon Ah Park, MD, Yong Beom Cho, MD, PhD, Seong Hyeon Yun, MD, PhD, Hee Cheol Kim, MD, PhD, Woo Yong Lee, MD, PhD, Kiyoun Kim, MS, Kyunga Kim, PhD, Dong Kyung Chang, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2017

Login to get access

Abstract

Background

The survival benefit of extensive colectomy is controversial in Lynch syndrome, and risk factors for metachronous colorectal cancer (CRC) after segmental colectomy are unclear.

Objective

The aim of this study was to investigate the survival outcome and risk of metachronous CRC after surgery in Lynch syndrome patients diagnosed with their first CRC.

Methods

Overall, 106 patients with Lynch syndrome who underwent surgery for CRC were included in the study. The demographics, genotype, clinicopathological characteristics of the index CRC, and follow-up data were reviewed from a single-institution Lynch syndrome database.

Results

Of 30 patients who underwent extensive surgery, no metachronous CRC was developed during a mean follow-up of 68.1 months. Of 76 patients who underwent segmental colectomy, 13 (17.1 %) developed metachronous CRC during a mean follow-up of 77.2 months. The cumulative risk of metachronous CRC was 8.4 % at 5 years and 20.4 % at 10 years after segmental colectomy. No difference in overall and CRC-specific survival was observed between segmental colectomy and extensive colectomy (p = 0.277 and p = 0.659, respectively). A 25 cm or longer resection of bowel decreased the risk of metachronous CRC after segmental colectomy compared with less extensive resection (hazard ratio 0.10, 95 % confidence interval 0.01–0.86). Annual surveillance colonoscopy did not decrease the risk of metachronous CRC compared with less frequent surveillance colonoscopy. Although not statistically significant, none of the MSH6 gene mutation carriers were diagnosed with metachronous CRC.

Conclusions

Although no survival benefit was identified, surgeons and patients might consider extensive colectomy to prevent metachronous CRC in Lynch syndrome patients regardless of their clinicopathological characteristics.
Appendix
Available only for authorised users
Literature
1.
Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMedPubMedCentral
2.
Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76:1–18.CrossRefPubMedPubMedCentral
3.
Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.CrossRefPubMed
4.
Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007;44:353–62.CrossRefPubMedPubMedCentral
5.
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109:1159–79.CrossRefPubMed
6.
Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.CrossRefPubMedPubMedCentral
7.
Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–7.CrossRefPubMed
8.
de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52:1752–5.CrossRefPubMedPubMedCentral
9.
Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum. 2012;55:653–9.CrossRefPubMed
10.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
11.
Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer. 2008;7:41–52.CrossRefPubMed
12.
Chang DK, Ricciardiello L, Goel A, Chang CL, Boland CR. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem. 2000;275:29178.PubMed
13.
de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. 2002;45:1588–94.CrossRefPubMed
14.
Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:174–82.CrossRefPubMed
15.
Stuckless S, Green JS, Morgenstern M, et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet. 2012;82:439–45.CrossRefPubMed
16.
Vasen HF, Abdirahman M, Brohet R, et al. One to two-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300–6.CrossRefPubMed
17.
Win AK, Parry S, Parry B, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol. 2013;20:1829–36.CrossRefPubMedPubMedCentral
18.
Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum. 2010;53:77–82.CrossRefPubMed
19.
Pylvanainen K, Lehtinen T, Kellokumpu I, Jarvinen H, Mecklin JP. Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer. 2012;11:467–71.CrossRefPubMed
20.
Karlitz JJ, Hsieh MC, Liu Y, et al. Population-based Lynch syndrome screening by microsatellite instability in patients ≤50: prevalence, testing determinants, and result availability prior to colon surgery. Am J Gastroenterol. 2015;110:948–55.CrossRefPubMed
21.
Rubenstein JH, Enns R, Heidelbaugh J, Barkun A; Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the diagnosis and management of Lynch syndrome. Gastroenterology. 2015;149:777–82 (Quiz e16–7).CrossRefPubMed
Metadata
Title
Survival Outcome and Risk of Metachronous Colorectal Cancer After Surgery in Lynch Syndrome
Authors
Tae Jun Kim, MD
Eun Ran Kim, MD
Sung Noh Hong, MD, PhD
Young-Ho Kim, MD, PhD
Jung Wook Huh, MD, PhD
Yoon Ah Park, MD
Yong Beom Cho, MD, PhD
Seong Hyeon Yun, MD, PhD
Hee Cheol Kim, MD, PhD
Woo Yong Lee, MD, PhD
Kiyoun Kim, MS
Kyunga Kim, PhD
Dong Kyung Chang, MD, PhD
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5633-1

Other articles of this Issue 4/2017

Annals of Surgical Oncology 4/2017 Go to the issue

Melanomas

Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients

Pancreatic Tumors

Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor

Gastrointestinal Oncology

How Do We Bridge the West and the East in the Treatment for Gastric Cancer?

Gastrointestinal Oncology

Inflammation-Based Prognostic Scores: Utility in Prognostication and Patient Selection for Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with Peritoneal Metastasis of Colonic Origin

Thoracic Oncology

Long-Term Impact of Postoperative Complications on Cancer Recurrence Following Lung Cancer Surgery

Hepatobiliary Tumors

Robotic Hepatectomy: A New Paradigm in the Management of Hepatocellular Carcinoma?